(EMAILWIRE.COM, November 06, 2018 ) According to a new market research report "NGS-based RNA-seq Market by Products & Services (Sample Preparation, Consumables, Bioinformatics), Technology (SBS, SMRT), Application (De novo, Transcriptome Epigenetics, Small RNA), End User (Research Centers, BioPharma Companies) - Global Forecast to 2022" published by MarketsandMarkets™, this report studies the global NGS-based RNA-seq market over the forecast period of 2017 to 2022. The global NGS-based RNA-seq market is projected to reach USD 2.65 Billion by 2022 from USD 1.05 Billion in 2017, at a CAGR of 20.2%.

Don’t miss out on business opportunities in Lab Automation Market. Speak to our analyst and gain crucial industry insights that will help your business grow: https://tinyurl.com/y72hbsrv

Factors such as the advantages of RNA-seq over microarray technology, technological advancements in RNA-seq products, increasing number of RNA-seq grants, increasing number of research activities, and rapid growth in precision medicine are driving the growth of the market.

On the basis of product and service, the NGS-based RNA-seq market is categorized into sample preparation, sequencing platforms and consumables, sequencing services, and data analysis, storage, & management. In 2016, the sequencing platforms and consumables segment accounted for the largest share of the market. The data analysis, storage, and management is expected to register the highest CAGR during the forecast period primarily due to development of more efficient data analysis solutions and growing computational capabilities of data analytics providers.

Browse and in-depth TOC on "NGS-based RNA-seq Market"
42 – Tables
45 - Figures
153 - Pages

View more detailed TOC @ https://www.marketsandmarkets.com/Market-Reports/ngs-based-rna-seq-market-102977816.html

On the basis of technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. In 2016, the SBS technology accounted for the largest share of the market, majorly due to the development of new and advanced NGS platforms, the increasing demand for Illumina’s systems (including the HiSeq and MiSeq series) and the growing demand for NextSeq and HiSeq X Ten for RNA & DNA sequencing.

Based on applications, the market is categorized into four segments, namely, de novo transcriptome assembly, expression profiling analysis, variant calling & transcriptome epigenetics, and small RNA sequencing. The expression profiling analysis segment accounted for the major share of the global NGS-based RNA-Seq market.

Request Free Sample Pages @ https://www.marketsandmarkets.com/requestsample.asp?id=102977816

Geographically, the NGS-based RNA-seq market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest share of the market in 2016, followed by Europe. The market in North America is primarily driven by government support through funds for genomics research, advancements in RNA-seq products, growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in this region. However, Asia-Pacific is expected to register the highest growth rate during the forecast period from 2017 to 2022, due to the significant focus on R&D activities as a means of broadening the scope of RNA-seq applications and decreasing the costs of NGS products & services in this region.

The major players of the market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N. V. (Germany), Pacific Biosciences of California, Inc. (U.S.), BGI (China), Oxford Nanopore Technologies, Ltd. (U.K.), PerkinElmer, Inc. (U.S.), GATC Biotech AG (Germany), Agilent Technologies, Inc. (U.S.), Roche Holding AG (Switzerland), Macrogen, Inc. (South Korea), and Eurofins Scientific (Luxembourg).